Alimentary pharmacology & therapeutics
-
Aliment. Pharmacol. Ther. · Mar 2012
Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation.
Irritable bowel syndrome with constipation (IBS-C) significantly decreases quality of life and the ability to perform daily living activities. ⋯ In patients with irritable bowel syndrome with constipation, lubiprostone 8 mcg twice daily was found to be safe and well tolerated over 9-13 months of treatment.
-
Aliment. Pharmacol. Ther. · Mar 2012
Randomized Controlled TrialRandomised clinical trial: an assessment of acupuncture on specific meridian or specific acupoint vs. sham acupuncture for treating functional dyspepsia.
Functional dyspepsia (FD) is a common disease without an established optimal treatment. ⋯ Acupuncture is effective in the treatment of functional dyspepsia, and is superior to non-acupoint puncture. The benefit of acupuncture relies on acupoint specificity.
-
Aliment. Pharmacol. Ther. · Mar 2012
Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis.
Infliximab (IFX) therapy escalation during maintenance treatment occurs frequently in clinical practice in patients with ulcerative colitis (UC). Outcomes for these patients have not been described. ⋯ A significant proportion of ambulatory patients with UC treated with maintenance infliximab required therapy escalation over time. This was associated with lower remission, and higher colectomy, rates.